References
- Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis.46, 155–164 (2008).
- Projan SJ. Why is Big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol.6, 427–430 (2003).
- Falagas ME, Fragoulis KN, Karydis I. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. PLoS ONE20(1), e11 (2006).
- Dellit TH, Owens RC, McGowan JE et al. Infectious Disease Society of America and Society of Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis.44, 159–177 (2007).
- Price DB, Honeybourne D, Little P et al. Community-acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general practice. Respir. Med.98, 17–24 (2004).
Websites
- Guidance for Industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs www.fda.gov/cber/gdlns/iche14qtc.htm (Accessed 21 August 2008)
- Clinical trial design for community-acquired pneumonia; public workshop, January 17–18, 2008, Silver Springs, MD, USA www.fda.gov/cder/meeting/CAP.htm (Accessed 21 August 2008)